Figure 3. Changes in fatty acid metabolism in Abcd3 KO mice.

A) Urinary C6-DCA, C8-DCA, C10-DCA, and C12-DCA (in mmol/mol creatinine) in WT (n=4 males, n=4 females) and Abcd3 KO (n=6 males, n=5 females) fed mice. B) Liver dicarboxylylcarnitine profile (in pmol/mg tissue) in WT (n=5 fed, n=7 fasted) and Abcd3 KO (n=5 fed, n=7 fasted) mice. Dicarboxylylcarnitine species that could not be distinguished from other hydroxyacylcarnitine species with the same nominal mass (isobaric compounds) are marked with an asterisk, as indicated here: C8DC*/C12-OH; C10DC*/C14-OH; C12DC*/C16-OH; C14DC*/C18-OH. C) Liver medium- and long-chain acylcarnitine profile (in pmol/mg tissue) in WT (n=5 fed, n=7 fasted) and Abcd3 KO (n=5 fed, n=7 fasted) mice. D) Measured [U-¹³C]-labeled C8-DC-carnitine, and C10-DC-carnitine (in pmol/mg of tissue) in mouse liver slices after 4-hr incubation of WT and Abcd3 KO mouse liver slices (n=4) with [U-¹³C]-C12-DCA alone or with [U-¹³C]-C12-DCA + L-aminocarnitine (L-AC). E) Plasma medium- and long-chain acylcarnitine profile (in μmol/L) in WT (n=5) and Abcd3 (n=6) KO mice treated with L-AC and subjected to food withdrawal during the photophase. Individual values, the average and the standard deviation are graphed.* p<0.05; ** p<0.01; *** p<0.001 (two-way ANOVA in A-D; unpaired, two-tailed student t-test in E). The effects in the two-way ANOVA are indicated as follows; G: Genotype; S: Sex; F: Feeding; L: L-AC; I: Interaction.